Inclusion criteria (let op korte versie, zie full protocol voor details)
ECOG/WHO performance 0-1
Pathologically proven NSCLC, staged according to the 8th edition of the AJCC Staging Manual, with a clinical indication for concurrent CRT
Pathology proven N2 or N3 lymph node metastasis
The patient is able to receive concurrent CRT. (0=no, 1=yes)
The patient is operable to the discretion of the treating pulmonary physician, surgeon and anesthesiologist, based on lung function testing and performance scoring.
Key exclusion criteria
Exclusion criteria
Irresectable primary lung tumor before start of concurrent CRT.
Pneumonectomy deemed necessary (by the treating surgeon) to achieve a complete resection (R0).
Sulcus superior tumor with invasion of the thoracic wall.
cT3-4 based on satellite nodus/lesion in the ipsilateral lung.
Patients with a locoregional recurrence or a second primary lung cancer.
Patients with prior treatment with radiotherapy on the lung.
Patients with a history of other malignancies (for exceptions see full protocol)
Small cell lung cancer or a pulmonary carcinoid tumor.
